208 related articles for article (PubMed ID: 15544489)
21. Advances in the development of ribozymes and antisense oligodeoxynucleotides as antiviral agents for human papillomaviruses.
Alvarez-Salas LM; BenÃtez-Hess ML; DiPaolo JA
Antivir Ther; 2003 Aug; 8(4):265-78. PubMed ID: 14518695
[TBL] [Abstract][Full Text] [Related]
22. Antisense makes sense in engineered regenerative medicine.
Yao Y; Wang C; Varshney RR; Wang DA
Pharm Res; 2009 Feb; 26(2):263-75. PubMed ID: 19015958
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells.
Miyagishi M; Hayashi M; Taira K
Antisense Nucleic Acid Drug Dev; 2003 Feb; 13(1):1-7. PubMed ID: 12691531
[TBL] [Abstract][Full Text] [Related]
24. siRNA-mediated antitumorigenesis for drug target validation and therapeutics.
Lu PY; Xie FY; Woodle MC
Curr Opin Mol Ther; 2003 Jun; 5(3):225-34. PubMed ID: 12870431
[TBL] [Abstract][Full Text] [Related]
25. Antisense technologies have a future fighting neurodegenerative diseases.
Seidman S; Eckstein F; Grifman M; Soreq H
Antisense Nucleic Acid Drug Dev; 1999 Aug; 9(4):333-40. PubMed ID: 10463077
[TBL] [Abstract][Full Text] [Related]
26. Design of antisense oligonucleotides and short interfering RNA duplexes (siRNA) targeted to BCL6 mRNA: towards rational drug development for specific lymphoma subsets.
Kalota A; Opalinska JB
Blood Cells Mol Dis; 2007; 38(3):199-203. PubMed ID: 17254814
[TBL] [Abstract][Full Text] [Related]
27. Oligonucleotide therapeutics: clothing the emperor.
Gewirtz AM
Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
[TBL] [Abstract][Full Text] [Related]
28. Lipid Nanoparticle Systems for Enabling Gene Therapies.
Cullis PR; Hope MJ
Mol Ther; 2017 Jul; 25(7):1467-1475. PubMed ID: 28412170
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic nucleic acids: current clinical status.
Sridharan K; Gogtay NJ
Br J Clin Pharmacol; 2016 Sep; 82(3):659-72. PubMed ID: 27111518
[TBL] [Abstract][Full Text] [Related]
30. Antisense technology: a selective tool for gene expression regulation and gene targeting.
Sahu NK; Shilakari G; Nayak A; Kohli DV
Curr Pharm Biotechnol; 2007 Oct; 8(5):291-304. PubMed ID: 17979727
[TBL] [Abstract][Full Text] [Related]
31. Antisense technologies in the studying of Toxoplasma gondii.
Crater AK; Roscoe S; Roberts M; Ananvoranich S
J Microbiol Methods; 2017 Jul; 138():93-99. PubMed ID: 26724749
[TBL] [Abstract][Full Text] [Related]
32. RNAi: a novel antisense technology and its therapeutic potential.
Dallas A; Vlassov AV
Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic potential and mechanism of action of oligonucleotides and ribozymes.
Lavrovsky Y; Chen S; Roy AK
Biochem Mol Med; 1997 Oct; 62(1):11-22. PubMed ID: 9367793
[TBL] [Abstract][Full Text] [Related]
34. Antisense applications for biological control.
Pan WH; Clawson GA
J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307
[TBL] [Abstract][Full Text] [Related]
35. The development and future of oligonucleotide-based therapies for cervical cancer.
Gu W; Putral LN; Irving A; McMillan NA
Curr Opin Mol Ther; 2007 Apr; 9(2):126-31. PubMed ID: 17458165
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic applications of catalytic antisense RNAs (ribozymes).
Rossi JJ
Ciba Found Symp; 1997; 209():195-204; discussion 204-6. PubMed ID: 9383577
[TBL] [Abstract][Full Text] [Related]
37. Colocalization of antisense RNAs and ribozymes with their target mRNAs.
Arndt GM; Rank GH
Genome; 1997 Dec; 40(6):785-97. PubMed ID: 9449790
[TBL] [Abstract][Full Text] [Related]
38. Development of ribozymes that target stathmin, a major regulator of the mitotic spindle.
Mistry SJ; Benham CJ; Atweh GF
Antisense Nucleic Acid Drug Dev; 2001 Feb; 11(1):41-9. PubMed ID: 11258620
[TBL] [Abstract][Full Text] [Related]
39. The potential application of ribozymes for the treatment of hematological disorders.
James HA
J Leukoc Biol; 1999 Sep; 66(3):361-8. PubMed ID: 10496304
[TBL] [Abstract][Full Text] [Related]
40. Assessment of an anti-HIV-1 combination gene therapy strategy using the antisense RNA and multimeric hammerhead ribozymes.
Ramezani A; Ma XZ; Ameli M; Arora A; Joshi S
Front Biosci; 2006 Sep; 11():2940-8. PubMed ID: 16720366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
